Morgan Stanley upgraded Dexcom Inc (DXCM) to Overweight from Equal-Weight on December 1, 2025. The current share price stands at $64.30.
This upgrade reflects a more favorable outlook on the company's prospects, suggesting improved fundamentals or business performance. Dexcom, headquartered in San Diego, California, specializes in the design and commercialization of glucose monitoring systems for diabetes management. The firm employs approximately 10,300 people and has a market capitalization of $24.3 billion.
Dexcom's key metrics include a P/E ratio of 33.67 and an EPS of 1.77. The company is set to announce its next earnings on July 28, 2026, with an estimated EPS of $0.60 and revenue of $1.3 billion. Recent earnings have shown a positive trend, including a Q3 2025 EPS of $0.61, surpassing estimates by 5.3%.
As of December 1, 2025, the analyst consensus for Dexcom indicates 16 Strong Buy, 15 Buy, and 6 Hold ratings, with no Sell or Strong Sell ratings. This update provides insight into the shifting analyst sentiment toward the company, which could be influenced by its ongoing innovation in continuous glucose monitoring technology, including products like the Dexcom G6 and G7 systems.